Expression of Chemokine Receptor CCR6 as a Molecular Determinant of Adrenal Metastatic Relapse in Patients With Primary Lung Cancer

Christophe M. Raynaud; Olaf Mercier; Philippe Dartevelle; Frédéric Commo; Ken André Olaussen; Vincent de Montpreville; Fabrice André; Laure Sabatier; Jean-Charles Soria

Disclosures

Clin Lung Cancer. 2010;11(3):187-191.

Conclusion

Although we acknowledge the lack of functional validation and the limited size of our patient population, we believe the statistical difference observed between CCR6 expression in adrenal metastases and corresponding primary tumors suggests a role for the CCR6 receptor in the organ orientation of adrenal metastases in lung cancer. Our results support the possibility that circulating CCR6-expressing tumor cells are oriented toward the adrenal gland by the adrenal CCL20 expression in patients with NSCLC.

1 2 3 4 5

Next Section

Acknowledgments
The work in the Laure Sabatier laboratory was supported by TELINCA (Telomere Research Program of the Institut National du Cancer) and RISC-RAD (Radiosensitivity of Individuals and Susceptibility to Cancer Induced by Ionizing Radiations; contract number FI6R-CT2003-508842). We thank Dr. Fabrizio D'Adda di Fagagna for his interactions and helpful discussions. Christophe Raynaud is a doctoral fellow funded by a CEA (Commissariat à l'Energie Atomique)-Lilly Fellowship.

Cite this: Expression of Chemokine Receptor CCR6 as a Molecular Determinant of Adrenal Metastatic Relapse in Patients With Primary Lung Cancer - Medscape - May 01, 2010.

Table 1. Patient Characteristics (N = 21)
Characteristic	Number of Patients (%)
Median Age at Diagnosis, Years (Range)	53 (42–42)
Sex
Male	17 (81)
Female	4 (19)
Stage at Diagnosis (TNM)
I	0
II	12 (57.2)
III	7 (33.3)
IV	2 (9.5)
Histology
Adenocarcinoma	11 (52.4)
Squamous cell carcinoma	9 (42.9)
Large-cell carcinoma	1 (4.7)
Timing of Metastases
Synchronous	5 (23.8)
Metachronous	16 (16)

Abbreviation: TNM = tumor-node-metastasis

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.